We are a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body’s natural healing process. We believe our non-invasive medical device and biologic products play a critical role in supporting the body’s own healing mechanisms to heal or eliminate the pain caused by orthopedic conditions and problems, which we define as our active healing products. Our products are in three categories: 1. OA (osteoarthritis) joint pain treatment and joint preservation – injectable treatments; 2. bone graft substitutes, and 3. a minimally invasive fracture treatment that uses pulsed ultrasound.
These products address an estimated $6.0 billion market opportunity across osteoarthritic, or OA, joint pain treatment and joint preservation, spinal fusion surgery and bone fractures, each of which is experiencing growth through multiple industry tailwinds, including an aging population, increased participation in sports and active lifestyles, and a rise in obesity rates. Our devices are most often used to delay or replace the need for an elective surgical procedure and are focused on reaching patients early on in their treatment paradigm. In 2019, approximately 85% of our $340.1 million in revenues were derived from products associated with non-surgical procedures.
|Industry:||SURGICAL & MEDICAL INSTRUMENTS & APPARATUS|
|Address||4721 Emperor Boulevard, Suite 100 Durham, North Carolina 27703|
|Phone Number||(919) 474-6700|
|View Prospectus:||Bioventus Inc.|
|Revenues||$320.12 mil (last 12 months)|
|Net Income||$17.78 mil (last 12 months)|
|Price range||$13.00 - $13.00|
|Est. $ Volume||$104.0 mil|
|Manager / Joint Managers||Morgan Stanley/ J.P. Morgan/ Goldman Sachs/ Canaccord Genuity|
|Expected To Trade:||2/11/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|